Cognitive Protective Effect of Newer Antidiabetic Drugs
NCT ID: NCT05347459
Last Updated: 2022-07-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2022-03-02
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Explore the cognitive protective effects of SGLT2 inhibitors and DPP-4 inhibitors in patients attending diabetic clinics in Alexandria
2. Examine the possible relationship of such effects with the systemic inflammatory and metabolic status in these patients
3. Undertake a network analysis to elucidate the potential pathways linking the observed protective effects, if any, with the observed changes in inflammatory or metabolic parameters
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Metformin and DPP4 Inhibitors on Cognition and Cardiovascular Protection in Type 2 Diabetic Patients
NCT05429554
Vildagliptin in Older Adults With Diabetes and Mild Cognitive Impairment
NCT03819127
Effects of Saxagliptin on Endothelial Function
NCT01319357
Use of Incretins in Diabetic Patients
NCT03486964
Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.
NCT03714594
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The patients targeted will be divided into the following groups:
1. Diabetic patients treated with metformin and DPP-4 inhibitors and/or SGLT2 inhibitors
2. Diabetic patients treated with metformin only
This will be in addition to a group of healthy non-diabetic controls to serve as a baseline reference.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
New Antidiabetic
Type 2 diabetic patients receiving SGLT2 inhibitors and/or DPP-4 inhibitors with metformin
Dapagliflozin
usual and customary doses for type 2 diabetes management
Empagliflozin
usual and customary doses for type 2 diabetes management
Canagliflozin
usual and customary doses for type 2 diabetes management
Sitagliptin
usual and customary doses for type 2 diabetes management
Saxagliptin
usual and customary doses for type 2 diabetes management
Linagliptin
usual and customary doses for type 2 diabetes management
Vildagliptin
usual and customary doses for type 2 diabetes management
Traditional Antidiabetic
Type 2 diabetic patients treated with metformin
No interventions assigned to this group
Control
Healthy non-diabetic patients
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dapagliflozin
usual and customary doses for type 2 diabetes management
Empagliflozin
usual and customary doses for type 2 diabetes management
Canagliflozin
usual and customary doses for type 2 diabetes management
Sitagliptin
usual and customary doses for type 2 diabetes management
Saxagliptin
usual and customary doses for type 2 diabetes management
Linagliptin
usual and customary doses for type 2 diabetes management
Vildagliptin
usual and customary doses for type 2 diabetes management
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age (≥50 Years)
* Ability to understand and cooperate with study procedures
Exclusion Criteria
* Use of possible or known cognition impairing drugs in the last three months
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alexandria University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed El-Yazbi
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahmed F El-Yazbi, PhD
Role: PRINCIPAL_INVESTIGATOR
Professor of Pharmacology and Therapeutics, Alexandria University
Labiba El-Khordagui, PhD
Role: PRINCIPAL_INVESTIGATOR
Professor of Pharmaceutics, Alexandria University
Noha A Hamdy, PhD
Role: PRINCIPAL_INVESTIGATOR
Assistant Professor of Clinical Pharmacy, Alexandria University
Amr El-Feky, MD
Role: PRINCIPAL_INVESTIGATOR
Assistant Professor of Internal Medicine, Alexandria University
Shams T Osman, BPharm
Role: PRINCIPAL_INVESTIGATOR
Instructor of Clinical Pharmacy, Alexandria University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alexandria University
Alexandria, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DIAB-DRUG-COG-FUN-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.